Trikafta 100-50-75 MG/75MG PKT 14S
Ended Awarded
- Contract number
- SPE2DR26FDDQ0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,319
Award facts
- Contract value 100% obligated
- $19,318.55 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Trikafta 100-50-75 mg packets (14-count) valued at $19,318.55 under a firm fixed-price contract. The delivery order, issued on November 13, 2025, is part of DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. This underlying IDC, awarded on the same date, carries a ceiling value of $499.999 billion and an ultimate completion date of December 31, 2036, positioning DMS Pharmaceutical Group as a regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy. The contract contains no set-aside designation.
Under the PPV-G GEN V vehicle, DMS Pharmaceutical Group is authorized to supply a comprehensive range of pharmaceutical products—including branded and generic prescription medications, biologics, vaccines, and medical consumables—to support the medical supply needs of Department of Defense healthcare facilities worldwide. The company's established distribution network and track record of fulfilling diverse pharmaceutical requirements across multiple therapeutic categories demonstrate its capability to serve as a critical supplier for the federal military medical system. All identified delivery orders have been funded directly by the Defense Logistics Agency, with no subcontractor relationships identified in the award documentation.
Quick answers
Who was awarded contract SPE2DR26FDDQ0?
SPE2DR26FDDQ0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 13, 2025.
How much is contract SPE2DR26FDDQ0 worth?
The government has obligated $19,319 on SPE2DR26FDDQ0.
Is contract SPE2DR26FDDQ0 an order under another contract?
Yes. SPE2DR26FDDQ0 is a delivery order under SPE2DR25D9102, an indefinite delivery contract.
Was contract SPE2DR26FDDQ0 competed?
The extent of competition for SPE2DR26FDDQ0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award